Vascular-inducing poly(glycolic acid)-collagen nanocomposite-fiber scaffold.
For regenerative medicine with scaffolds, the immediate cellularization of the scaffold accompanied by angiogenesis inside is an important event. Such the aim is generally pursued by combining basic fibroblast growth factor (b-FGF) or vascular endothelial growth factor (VEGF) with the scaffold. In this study, we produced the nanocomposite nanofiber composed of poly(glycolic acid), PGA, and collagen to accomplish the recruitment of host cells and peripheral blood vessels without the bio-derived matter like growth factors. Structural analysis revealed that the fiber has the sheath-core like structure in which the surface region is abundant in PGA and the core region is abundant in collagen. This peculiar fibrous structure probably contributes the fragility of the fiber under the swelling in body fluid. The results of the animal experiment demonstrated that the PGA-collagen nanofiber sponge was entirely populated and vascularized within 5 days after the implantation. We hypothesized that the early fragmentation of the implanted fibrous sponge accelerated the host's inflammation reaction by phagocytized by macrophage, which followed by the recruitment of the fibroblasts and endothelial cells from the host tissue. Designing the suitable nanoscale structure of materials makes cellularization and vascularization of the scaffold possible without bio-derived factors.
International Center for Materials Nanoarchitectonics, National Institute for Materials Science, 1-2-1 Sengen, Tsukuba 305-0047, Japan. KOBAYASHI.Hisatoshi@nims.go.jp
Hisatoshi
H
Kobayashi
Dohiko
D
Terada
Yoshiro
Y
Yokoyama
Dae Won
DW
Moon
Yoshihiro
Y
Yasuda
Hiroyuki
H
Koyama
Tsuyoshi
T
Takato
D043925:Angiogenesis Inducing Agents / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D003094:Collagen / Q000737:chemistry / Q000494:pharmacology*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D051379:Mice; D008954:Models, Biological; D053761:Nanocomposites / Q000737:chemistry; D057139:Nanofibers / Q000737:chemistry; D018919:Neovascularization, Physiologic / Q000187:drug effects; D011100:Polyglycolic Acid / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013552:Swine; D023822:Tissue Engineering / Q000295:instrumentation / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage / Q000494:pharmacology
D043925:Angiogenesis Inducing Agents; D020099:Coated Materials, Biocompatible; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D011100:Polyglycolic Acid; D003094:Collagen